Erytech Pharma S.A. ERYTECH Announces FDA\'s Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States

Erytech Pharma S.A.: ERYTECH Announces FDA's Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States

Investigational New Drug Application reviewed and acceptedEnrollment of US patients expected to begin in Q3 2019Clinical trial authorizations now obtained in all twelve participating countries LYON...

More From BioPortfolio on "Erytech Pharma S.A.: ERYTECH Announces FDA's Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States"